Insulet (NASDAQ:PODD) Sets New 12-Month Low – Should You Sell?

Insulet Corporation (NASDAQ:PODD)’s stock price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $220.28 and last traded at $226.71, with a volume of 300006 shares trading hands. The stock had previously closed at $236.07.

Analyst Upgrades and Downgrades

Several research firms have commented on PODD. Evercore set a $340.00 price objective on shares of Insulet in a research note on Thursday, February 19th. UBS Group restated a “buy” rating on shares of Insulet in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research note on Thursday, January 22nd. Oppenheimer reduced their price objective on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Finally, Barclays reissued an “underweight” rating and issued a $286.00 price objective on shares of Insulet in a research note on Thursday, February 19th. Twenty analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $354.24.

Insulet Stock Down 5.6%

The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The business has a 50-day simple moving average of $259.73 and a 200-day simple moving average of $298.06. The company has a market cap of $15.69 billion, a PE ratio of 63.64, a P/E/G ratio of 1.43 and a beta of 1.42.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. During the same period in the prior year, the company posted $1.15 EPS. The business’s quarterly revenue was up 31.2% on a year-over-year basis. Equities research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insiders Place Their Bets

In other news, Director Michael R. Minogue acquired 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were bought at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Winnow Wealth LLC acquired a new position in Insulet during the 3rd quarter worth $862,000. Illinois Municipal Retirement Fund lifted its holdings in shares of Insulet by 41.3% during the second quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier’s stock worth $3,780,000 after purchasing an additional 3,514 shares during the period. Machina Capital S.A.S. purchased a new position in Insulet in the 3rd quarter valued at $2,778,000. ING Groep NV increased its stake in Insulet by 88.5% in the 3rd quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after buying an additional 8,123 shares during the period. Finally, Fisher Asset Management LLC lifted its stake in shares of Insulet by 38.1% in the 3rd quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock worth $14,286,000 after acquiring an additional 12,754 shares during the period.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.